By Nick Stride
Friday 16th November 2001 |
Text too small? |
![]() |
F&P Healthcare American Depositary Shares finished Wednesday's Nasdaq market trading at $US26.05, a gain of 44.7% on the $US18 at which they were sold to US and other institutions on Tuesday.
F&P chief executive Gary Paykel earlier this month rejected criticism from institutional shareholders and sharebroking analysts that the $US16-18 an ADS "indicative price" it had set for the sale of 17.6 million Healthcare shares was far too low.
At $US26.05 the shares sold had gained $35 million ($83.5 million) in value in two days.
Arcus Investment Management's Simon Botherway said the sale, as predicted, had resulted in "a massive value transfer from Australasian investors to North American investors. I can assure you I'm not the only person who's extremely unhappy with this."
Fund managers Alliance Capital, BT Funds Management and New Zealand Funds Management and sharebroker Credit Suisse First Boston had also warned the float was too cheaply priced.
Healthcare shares were trading on the local market today at $15.70, up from the $10.95 at which the float price valued them.
No comments yet
KMD Brands announces new Group Chief Financial Officer
Commerce Commission to issue SOI re Viridian application
FBU - Moody's affirms FBU Baa3/stable rating
Contact Energy FY25 Financial Results Presentation
NZX Chief Executive Mark Peterson to depart in April 2026
BRW - Expansion of Napier Production in Post-Cyclone Rebuild
July 24th Morning Report
Air New Zealand 2025 Annual Results Webcast Details
FPH provides Investor Event presentation
Tower to discontinue multi-policy discounts